Cargando…
Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV
Approximately 50% of people living with HIV (PLWH) in the United States are ≥50 years old. Clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) demonstrated potent efficacy and favorable safety in older PLWH; however, real-world data would be useful to validate these results....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462546/ https://www.ncbi.nlm.nih.gov/pubmed/34559154 http://dx.doi.org/10.1097/MD.0000000000027330 |
_version_ | 1784572226355331072 |
---|---|
author | Rolle, Charlotte-Paige Nguyen, Vu Patel, Kiran Cruz, Dan DeJesus, Edwin Hinestrosa, Federico |
author_facet | Rolle, Charlotte-Paige Nguyen, Vu Patel, Kiran Cruz, Dan DeJesus, Edwin Hinestrosa, Federico |
author_sort | Rolle, Charlotte-Paige |
collection | PubMed |
description | Approximately 50% of people living with HIV (PLWH) in the United States are ≥50 years old. Clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) demonstrated potent efficacy and favorable safety in older PLWH; however, real-world data would be useful to validate these results. Retrospective cohort study. We evaluated records from PLWH aged ≥50 years at the Orlando Immunology Center who were switched to B/F/TAF between February 2018 and August 2019. Eligible patients had baseline HIV-1 RNA <50 copies/mL and 48 weeks of follow-up data. The primary endpoint was maintenance of HIV-1 RNA <50 copies/mL at Week 48. The impact of switching to B/F/TAF on drug–drug interactions (DDIs) and safety parameters were also assessed. Three-hundred and fifty patients met inclusion criteria, median age was 57 years, 20% were women, and 43% were non-White. Fifty-five percent of patients switched from integrase inhibitor-based regimens; the most common reason for switch was simplification. At Week 48, 330 (94%) patients maintained an HIV-1 RNA <50 copies/mL and 20 (6%) had an HIV-1 RNA between 50 and 400 copies/mL. One-hundred and forty potential DDIs were identified in 121 (35%) patients taking a boosting agent or rilpivirine at baseline that were resolved after switching to B/F/TAF. Treatment-related adverse events occurred in 51 (15%) patients (all Grade 1–2) and led to 8 discontinuations. In this real-world cohort, switching to B/F/TAF was associated with maintenance of virologic control, and avoidance of DDIs in a large proportion of patients. These data support use of B/F/TAF as a treatment option in older PLWH. |
format | Online Article Text |
id | pubmed-8462546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-84625462021-09-27 Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV Rolle, Charlotte-Paige Nguyen, Vu Patel, Kiran Cruz, Dan DeJesus, Edwin Hinestrosa, Federico Medicine (Baltimore) 4850 Approximately 50% of people living with HIV (PLWH) in the United States are ≥50 years old. Clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) demonstrated potent efficacy and favorable safety in older PLWH; however, real-world data would be useful to validate these results. Retrospective cohort study. We evaluated records from PLWH aged ≥50 years at the Orlando Immunology Center who were switched to B/F/TAF between February 2018 and August 2019. Eligible patients had baseline HIV-1 RNA <50 copies/mL and 48 weeks of follow-up data. The primary endpoint was maintenance of HIV-1 RNA <50 copies/mL at Week 48. The impact of switching to B/F/TAF on drug–drug interactions (DDIs) and safety parameters were also assessed. Three-hundred and fifty patients met inclusion criteria, median age was 57 years, 20% were women, and 43% were non-White. Fifty-five percent of patients switched from integrase inhibitor-based regimens; the most common reason for switch was simplification. At Week 48, 330 (94%) patients maintained an HIV-1 RNA <50 copies/mL and 20 (6%) had an HIV-1 RNA between 50 and 400 copies/mL. One-hundred and forty potential DDIs were identified in 121 (35%) patients taking a boosting agent or rilpivirine at baseline that were resolved after switching to B/F/TAF. Treatment-related adverse events occurred in 51 (15%) patients (all Grade 1–2) and led to 8 discontinuations. In this real-world cohort, switching to B/F/TAF was associated with maintenance of virologic control, and avoidance of DDIs in a large proportion of patients. These data support use of B/F/TAF as a treatment option in older PLWH. Lippincott Williams & Wilkins 2021-09-24 /pmc/articles/PMC8462546/ /pubmed/34559154 http://dx.doi.org/10.1097/MD.0000000000027330 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | 4850 Rolle, Charlotte-Paige Nguyen, Vu Patel, Kiran Cruz, Dan DeJesus, Edwin Hinestrosa, Federico Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV |
title | Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV |
title_full | Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV |
title_fullStr | Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV |
title_full_unstemmed | Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV |
title_short | Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV |
title_sort | real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with hiv |
topic | 4850 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462546/ https://www.ncbi.nlm.nih.gov/pubmed/34559154 http://dx.doi.org/10.1097/MD.0000000000027330 |
work_keys_str_mv | AT rollecharlottepaige realworldefficacyandsafetyofswitchingtobictegraviremtricitabinetenofoviralafenamideinolderpeoplelivingwithhiv AT nguyenvu realworldefficacyandsafetyofswitchingtobictegraviremtricitabinetenofoviralafenamideinolderpeoplelivingwithhiv AT patelkiran realworldefficacyandsafetyofswitchingtobictegraviremtricitabinetenofoviralafenamideinolderpeoplelivingwithhiv AT cruzdan realworldefficacyandsafetyofswitchingtobictegraviremtricitabinetenofoviralafenamideinolderpeoplelivingwithhiv AT dejesusedwin realworldefficacyandsafetyofswitchingtobictegraviremtricitabinetenofoviralafenamideinolderpeoplelivingwithhiv AT hinestrosafederico realworldefficacyandsafetyofswitchingtobictegraviremtricitabinetenofoviralafenamideinolderpeoplelivingwithhiv |